Expertise in
8
conditions

Fabrice Bonnet

Tours, FR 
Expertise in
8
conditions
Tours, FR 

Overview

Fabrice Bonnet practices in Tours, France. Mr. Bonnet is highly rated in 8 conditions, according to our data. His top areas of expertise are HIV/AIDS, Type 2 Diabetes (T2D), Cryoglobulinemia, Hormone Replacement Therapy (HRT), and Oophorectomy.

His clinical research consists of co-authoring 357 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Male

Locations

Tours, France
Other Locations
Bordeaux, 33076, France
Rennes, France
Paris, France
Villejuif, France
Saint-andre-la-cote, France
Talence, France
4 Rue Larrey, Angers, 49100, France
4 Rue De La Chine, UMRS-938, Chine, France
Thenon, 75020, France
Avenue Du M.L. Koenig, Reims, 51092, France
CHU
Rouen, France
Pointe À Pitre, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Aging With HIV and Neurocognitive Decline, a Follow-up Study
Aging With HIV and Neurocognitive Decline, a Follow-up Study
Enrollment Status: Completed
Publish Date: January 30, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Phase IIIb, Open-label, Hybrid Type III Trial Evaluating Implementation Strategies for Long-acting Cabotegravir Plus Long-acting Rilpivirine Every Two Months in HIV-1 Infected, Virologically Suppressed Adults in Select European Healthcare Settings
A Phase IIIb, Open-label, Hybrid Type III Trial Evaluating Implementation Strategies for Long-acting Cabotegravir Plus Long-acting Rilpivirine Every Two Months in HIV-1 Infected, Virologically Suppressed Adults in Select European Healthcare Settings
Enrollment Status: Completed
Publish Date: April 05, 2024
Intervention Type: Drug, Other
Study Drug: Cabotegravir
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: October 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Current antiretroviral regimen
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Tenofovir alafenamide based regimen
Study Phase: Phase 3
Prevention of Symptomatic Venous Thromboembolism by Low Molecular Weight Heparin in Hospitalized Medical Patients Aged 70 Years and Older : a Randomized Placebo-Controlled Study The SYMPTOMS (SYstematic Elderly Medical Patients Thromboprophylaxis : Efficacy on Symptomatic OutcoMeS) Study
Prevention of Symptomatic Venous Thromboembolism by Low Molecular Weight Heparin in Hospitalized Medical Patients Aged 70 Years and Older : a Randomized Placebo-Controlled Study The SYMPTOMS (SYstematic Elderly Medical Patients Thromboprophylaxis : Efficacy on Symptomatic OutcoMeS) Study
Enrollment Status: Completed
Publish Date: July 05, 2022
Intervention Type: Drug
Study Drug: Enoxaparin
Study Phase: Phase 3
Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases
Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases
Enrollment Status: Completed
Publish Date: February 03, 2022
Intervention Type: Biological
Anemil Trial : Phase I/II Clinical Trial Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment
Anemil Trial : Phase I/II Clinical Trial Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment
Enrollment Status: Completed
Publish Date: February 18, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Residual Immune Activation in HIV-infected Patients on Successful cART: Association Between Inflammasome Activation in Monocytes by Circulating Metabolites and Non AIDS Defining Comorbidities
Residual Immune Activation in HIV-infected Patients on Successful cART: Association Between Inflammasome Activation in Monocytes by Circulating Metabolites and Non AIDS Defining Comorbidities
Enrollment Status: Completed
Publish Date: September 28, 2018
Intervention Type: Other
View 7 Less Clinical Trials

354 Total Publications

Response to the letter: Health outcomes of testosterone therapy in transgender men: methodological issues warrant caution.
Response to the letter: Health outcomes of testosterone therapy in transgender men: methodological issues warrant caution.
Journal: European journal of endocrinology
Published: December 19, 2025

Frequently Asked Questions about Fabrice Bonnet

Is Fabrice Bonnet a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Fabrice Bonnet is classified as an Distinguished expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Fabrice Bonnet participate in research or clinical trials?

Yes. Fabrice Bonnet has published 354 articles and abstracts on conditions like HIV/AIDS. You can view a list of Fabrice Bonnet's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bonnet's expertise for a condition
ConditionClose
    View All 86 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile